These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16214443)

  • 1. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.
    Tani S; Watanabe I; Anazawa T; Kawamata H; Tachibana E; Furukawa K; Sato Y; Nagao K; Kanmatsuse K; Kushiro T;
    Am J Cardiol; 2005 Oct; 96(8):1089-94. PubMed ID: 16214443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
    Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T
    J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment.
    Tani S; Nagao K; Anazawa T; Kawamata H; Iida K; Matsumoto M; Sato Y; Hirayama A
    Atherosclerosis; 2008 Jun; 198(2):360-5. PubMed ID: 18374337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography.
    Ito T; Ichihashi T; Fujita H; Sugiura T; Ohte N
    Heart Vessels; 2018 Apr; 33(4):351-357. PubMed ID: 29067491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Fuji T; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):28-34. PubMed ID: 18594477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Circ J; 2020 Sep; 84(10):1837-1845. PubMed ID: 32863287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein size, pravastatin treatment, and coronary events.
    Campos H; Moye LA; Glasser SP; Stampfer MJ; Sacks FM
    JAMA; 2001 Sep; 286(12):1468-74. PubMed ID: 11572739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.
    Zhang B; Miura S; Yanagi D; Noda K; Nishikawa H; Matsunaga A; Shirai K; Iwata A; Yoshinaga K; Adachi H; Imaizumi T; Saku K
    Atherosclerosis; 2008 Dec; 201(2):353-9. PubMed ID: 18395728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease.
    Matsuo Y; Kubo T; Okumoto Y; Ishibashi K; Komukai K; Tanimoto T; Ino Y; Kitabata H; Hirata K; Imanishi T; Akagi H; Akasaka T
    Eur Heart J Cardiovasc Imaging; 2013 Jan; 14(1):43-50. PubMed ID: 22573905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
    Lee SJ; Sacks FM
    Am J Cardiol; 2003 Jul; 92(2):121-4. PubMed ID: 12860210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease.
    Miyazaki T; Shimada K; Sato O; Kotani K; Kume A; Sumiyoshi K; Sato Y; Ohmura H; Watanabe Y; Mokuno H; Daida H
    Atherosclerosis; 2005 Mar; 179(1):139-45. PubMed ID: 15721020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
    Tanaga K; Bujo H; Inoue M; Mikami K; Kotani K; Takahashi K; Kanno T; Saito Y
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):662-6. PubMed ID: 11950707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. - Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol -.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Washio T; Kumabe N; Hirayama A
    Circ J; 2010 May; 74(5):954-61. PubMed ID: 20234098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in plasma malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction.
    Kametsu Y; Kitagawa Y; Sekiyama S; Takagi S
    Tokai J Exp Clin Med; 2005 Sep; 30(3):171-6. PubMed ID: 16285608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
    Rosenson RS; Otvos JD; Freedman DS
    Am J Cardiol; 2002 Jul; 90(2):89-94. PubMed ID: 12106834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma level of malondialdehyde-modified low-density lipoprotein with coronary plaque morphology in patients with coronary spastic angina: implication of acute coronary events.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Fuji T; Takahashi H; Iida K; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    Int J Cardiol; 2009 Jun; 135(2):202-6. PubMed ID: 18614250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.